Floatz logo

Orelabrutinib

Helicobacter Pylori Infection

Fudan UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

1 Active assets in the Helicobacter Pylori Infection cohort.

Asset / SponsorPhaseRating
BISMUTH SALICYLATE
Fatih Sultan Mehmet Training and Research Hospital
Phase 4BB
Huazhi Rougan Granule
Nanjing First Hospital, Nanjing Medical University
N/AD

Same molecule, other indications

Orelabrutinib is also rated in:

marginal zone lymphomaDormant
BBB
Indicative ·
73 / 100
View asset →
primary central nervous system lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →